Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
The goal of the current proposal is to examine if sublingual riluzole can reduce anxiety in
people with social anxiety disorder during a public speaking task.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Yale University
Collaborators:
Biohaven Pharmaceuticals Inc. Biohaven Pharmaceuticals, Inc.